ViiV’s HIV therapy Triumeq shows efficacy in women
ViiV Healthcare’s Triumeq has come out on top in a late-stage study pitting its effectiveness in treating women with HIV against that of an atazanavir-based regimen.
Read More
Tag: ARIA
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
